Lipitor (Atorvastatin): What to Expect, Week-by-Week First Month

The Timeline the Label Sets

The Lipitor label sets three practical markers for the first month: one tablet daily at any time of day with or without food; assess LDL-C when clinically appropriate, as early as 4 weeks after starting; and adjust the dose if the result calls for it [1]. The usual adult starting dose is 10 to 20 mg once daily, the range is 10 to 80 mg, and people who need an LDL-C reduction greater than 45% may start at 40 mg [1].

Week 1: The Drug Is in Your Blood Within Hours

Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the enzyme that converts HMG-CoA to mevalonate [1]. The label describes it lowering plasma cholesterol by inhibiting hepatic cholesterol synthesis and raising the number of hepatic LDL receptors, with more LDL uptake and catabolism [1]. The parent drug is active, and its ortho- and parahydroxylated metabolites are equally active in vitro [1].

Peak plasma concentration arrives 1 to 2 hours after a dose, absolute bioavailability of the parent drug is about 14%, and the half-life of atorvastatin is about 14 hours, with a half-life of 20 to 30 hours for its inhibitory activity [1]. About 70% of circulating inhibitory activity comes from active metabolites [1]. Food lowers Cmax about 25% and AUC about 9% without changing LDL-C reduction, and evening dosing gives about 30% lower Cmax and AUC than morning dosing, with the same LDL-C reduction at any time of day [1].

Muscle Symptoms to Watch For During the First Month

Myopathy and rhabdomyolysis are the label's central warning, and it notes acute kidney injury from myoglobinuria and rare fatalities with statins, including Lipitor [1]. Risk factors listed are age 65 or older, uncontrolled hypothyroidism, renal impairment, interacting drugs and higher doses [1]. The label directs patients to promptly report unexplained muscle pain, tenderness or weakness, particularly when accompanied by malaise or fever, and says Lipitor should be discontinued if markedly elevated CK levels occur or myopathy is diagnosed or suspected [1]. Rare immune-mediated necrotizing myopathy has also been reported with statins; it causes proximal muscle weakness and elevated CK that persist after the statin is stopped [1].

In the pooled placebo-controlled trials, myalgia occurred in 3.5% on Lipitor versus 3.1% on placebo, muscle spasms in 3.6% versus 3.0%, and musculoskeletal pain in 3.8% versus 3.6% [1]. Myalgia was the most common reason for stopping that exceeded placebo, at 0.7% [1].

Interactions matter if a new prescription is added during month one. Atorvastatin is a CYP3A4 substrate; clarithromycin 500 mg twice daily raised its AUC 4.54-fold and itraconazole 200 mg daily raised it 3.32-fold, and the label says not to exceed Lipitor 20 mg daily with either drug and 40 mg daily with nelfinavir [1]. Diltiazem 240 mg daily raised atorvastatin AUC 1.51-fold [1]. The label says concomitant use of cyclosporine or gemfibrozil with Lipitor is not recommended [1].

Week 4: The LDL-C Check and the Dose Decision

The label says to assess LDL-C when clinically appropriate, as early as 4 weeks after starting, and adjust the dose if necessary [1]. The expected size of the drop depends on the dose. In pooled 6-week data from patients with primary hyperlipidemia, mean LDL-C change from baseline was:

• 10 mg: -39%
• 20 mg: -43%
• 40 mg: -50%
• 80 mg: -60%
• placebo: +4%

All from the label's dose-response data [1].

Side-Effect Rates the Trials Recorded

From the pooled 17-trial table, comparing any-dose Lipitor with placebo: nasopharyngitis 8.3% versus 8.2%, arthralgia 6.9% versus 6.5%, diarrhea 6.8% versus 6.3%, pain in extremity 6.0% versus 5.9%, urinary tract infection 5.7% versus 5.6%, dyspepsia 4.7% versus 4.3%, nausea 4.0% versus 3.5%, and insomnia 3.0% versus 2.9% [1]. The reasons for stopping that occurred more often than on placebo were myalgia 0.7%, diarrhea 0.5%, nausea 0.4%, ALT increase 0.4% and hepatic enzyme increase 0.4% [1]. These rates cover a median treatment duration of 53 weeks, so they are not first-month rates, and the label does not report them week by week [1].

If a higher dose is chosen, the TNT trial compared 80 mg (n=4,995) with 10 mg (n=5,006) over a median of 4.9 years: discontinuation for adverse reactions 9.9% versus 8.1%, serious adverse reactions 1.8% versus 1.4%, and persistent transaminase elevations 1.3% versus 0.2% on the label's figures [1].

Liver Tests and Blood Sugar in Month One

The label says to consider liver enzyme testing before starting Lipitor and when clinically indicated thereafter [1]. Persistent transaminase rises above 3 times the upper limit of normal occurred in about 0.7% of patients in clinical trials, and by dose in 0.2% (10 mg), 0.2% (20 mg), 0.6% (40 mg) and 2.3% (80 mg) [1]. Rare fatal and non-fatal hepatic failure has been reported with statins [1]. The label's contraindications are acute liver failure or decompensated cirrhosis, and hypersensitivity to atorvastatin or an excipient [1].

Increases in HbA1c and fasting serum glucose have been reported with statins, including Lipitor [1]. In SPARCL, diabetes was reported as an adverse reaction in 6.1% of patients on Lipitor 80 mg versus 3.8% on placebo [1].

Timing, Food, Grapefruit and a Missed Dose

The Lipitor label permits once-daily dosing at any time of day, with or without food [1]. Grapefruit is a quantity question rather than an all-or-nothing rule: the label says to avoid large quantities, more than 1.2 liters daily, and notes that 240 mL of grapefruit juice daily raised the AUC of a single 40 mg dose 1.37-fold, with greater increases (AUC up to 2.5-fold) reported at 750 mL to 1.2 liters per day [1]. If a dose is missed, the label says not to take it and to resume with the next scheduled dose [1].

Groups Where the First Month Looks Different

In healthy adults aged 65 or older, Cmax is about 40% higher and AUC about 30% higher than in younger adults [1]. Renal disease does not change atorvastatin concentrations or LDL-C reduction, and there is no renal dose adjustment [1]. Renal impairment is still listed as a myopathy risk factor [1].

Pregnancy is not a contraindication in the current label. It says to discontinue Lipitor when pregnancy is recognized, or alternatively to consider the ongoing therapeutic needs of the patient, and that decades of observational data with statins in pregnancy have not identified a risk of major congenital malformations [1]. Breastfeeding is not recommended during treatment [1].